Abstract

Several circulating miRNAs identified in the plasma of smokers have been implicated as promoters of nasopharyngeal and lung carcinoma. To investigate the plasma profile of miRNAs in subjects who reduces the number of smoked cigarettes and who quit after six months. We accompanied 28 individuals enrolled in a Smoking Cessation Program over 6 months. At Baseline, clinical characteristics, co-morbidities, and smoking history were similar among subjects. After 6 months, two groups were defined: who successfully quitted smoking (named “quitters”, n = 18, mean age 57 years, 11 male) and who reduced the number of cigarettes smoked (20–90%) but failed to quit smoking (named “smokers”, n = 10, mean age 52 years, 3 male). No significant clinical changes were observed between groups at baseline and after a 6-month period, however, quitters showed significant downregulations in seven miRNAs at baseline: miR-17 (− 2.90-fold, p = 0.029), miR-20a (− 3.80-fold, p = 0.021); miR-20b (− 4.71-fold, p = 0.027); miR-30a (− 3.95-fold, p = 0.024); miR-93 (− 3.63-fold, p = 0.022); miR-125a (− 1.70-fold, p = 0.038); and miR-195 (− 5.37-fold, p = 0.002), and after a 6-month period in 6 miRNAs: miR-17 (− 5.30-fold, p = 0.012), miR-20a (− 2.04-fold, p = 0.017), miR-20b (− 5.44-fold, p = 0.017), miR-93 (− 4.00-fold, p = 0.041), miR-101 (− 4.82-fold, p = 0.047) and miR-125b (− 3.65-fold, p = 0.025). Using time comparisons, only quitters had significant downregulation in miR-301b (− 2.29-fold, p = 0.038) after 6-month. Reductions in the number of smoked cigarettes was insufficient to change the plasma profile of miRNA after 6 months. Only quitting smoking (100% reduction) significantly downregulated miR-301b related to hypoxic conditions, promotion of cell proliferation, decreases in apoptosis, cancer development, and progression as increases in radiotherapy and chemotherapy resistance.

Details

Title
Smoking load reduction is insufficient to downregulate miR-301b, a lung cancer promoter
Author
dos Santos Arcas Camila 1 ; Lin-Wang, Hui Tzu 2 ; Umeda Iracema Ioco Kikuchi 3 ; de Sousa Márcio Gonçalves 2 ; Utiyama Daniela Mitiyo Odagiri 4 ; de Padua Mansur Antonio 5 ; Macchione Mariangela 6 ; Hirata, Mario Hiroyuki 7 ; Nakagawa, Naomi Kondo 1 

 Faculdade de Medicina da Universidade de São Paulo, Department of Physiotherapy, LIM-54, São Paulo, Brazil (GRID:grid.11899.38) (ISNI:0000 0004 1937 0722) 
 Dante Pazzanese Institute of Cardiology São Paulo State, São Paulo, Brazil (GRID:grid.417758.8) (ISNI:0000 0004 0615 7869) 
 Faculdade de Medicina da Universidade de São Paulo, Department of Physiotherapy, LIM-54, São Paulo, Brazil (GRID:grid.11899.38) (ISNI:0000 0004 1937 0722); Dante Pazzanese Institute of Cardiology São Paulo State, São Paulo, Brazil (GRID:grid.417758.8) (ISNI:0000 0004 0615 7869) 
 Faculdade de Medicina da Universidade de São Paulo, Medicine Rehabilitation Lucy Montoro Institute, São Paulo, Brazil (GRID:grid.11899.38) (ISNI:0000 0004 1937 0722) 
 Faculdade de Medicina da Universidade de São Paulo, Department of Cardiopneumology, São Paulo, Brazil (GRID:grid.11899.38) (ISNI:0000 0004 1937 0722) 
 Faculdade de Medicina da Universidade de São Paulo, Department of Pathology, LIM05, São Paulo, Brazil (GRID:grid.11899.38) (ISNI:0000 0004 1937 0722) 
 Universidade de São Paulo, Department of Clinical and Toxicological Analysis, School of Pharmaceutical Sciences, São Paulo, Brazil (GRID:grid.11899.38) (ISNI:0000 0004 1937 0722) 
Publication year
2020
Publication date
2020
Publisher
Nature Publishing Group
e-ISSN
20452322
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2473276634
Copyright
© The Author(s) 2020. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.